Litcius/Paper detail

Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation

Takahiro Itamiya, Toshihiko Komai, Hiroko Kanda, Yasuo Nagafuchi, Hyangri Chang, Shota Shibata, Hiroyuki Ishiura, Hirofumi Shoda, Tatsushi Toda, Keishi Fujio

2022Clinical Rheumatology11 citationsDOI

Topics & Concepts

CanakinumabMedicineAmyloidosisMEFVAA amyloidosisGermline mutationParaproteinemiaFamilial Mediterranean feverDiseaseProteinuriaGene mutationInternal medicineDermatologyMutationAnakinraGeneticsKidneyMultiple myelomaGeneBiologyAmyloidosis: Diagnosis, Treatment, OutcomesIgG4-Related and Inflammatory DiseasesRenal Diseases and Glomerulopathies
Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation | Litcius